StockNews.com started coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX – Free Report) in a research note issued to investors on Saturday morning. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.
Eagle Pharmaceuticals Stock Performance
Shares of EGRX stock opened at $4.58 on Friday. The firm has a market capitalization of $59.48 million, a price-to-earnings ratio of 3.88 and a beta of 0.51. Eagle Pharmaceuticals has a one year low of $3.21 and a one year high of $18.31. The company has a 50 day moving average price of $4.93 and a 200 day moving average price of $4.95.
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the company. Headlands Technologies LLC grew its position in Eagle Pharmaceuticals by 75.7% during the first quarter. Headlands Technologies LLC now owns 6,641 shares of the specialty pharmaceutical company’s stock valued at $35,000 after acquiring an additional 2,861 shares during the period. Tower Research Capital LLC TRC lifted its stake in shares of Eagle Pharmaceuticals by 623.9% in the 4th quarter. Tower Research Capital LLC TRC now owns 6,841 shares of the specialty pharmaceutical company’s stock valued at $36,000 after purchasing an additional 5,896 shares in the last quarter. Mackenzie Financial Corp purchased a new stake in shares of Eagle Pharmaceuticals during the 2nd quarter worth about $60,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Eagle Pharmaceuticals during the 2nd quarter worth about $65,000. Finally, Fidelis Capital Partners LLC acquired a new stake in Eagle Pharmaceuticals during the 2nd quarter worth approximately $71,000. 85.36% of the stock is owned by hedge funds and other institutional investors.
Eagle Pharmaceuticals Company Profile
Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.
Read More
- Five stocks we like better than Eagle Pharmaceuticals
- What to Know About Investing in Penny Stocks
- Columbia Sportswear: A Turnaround Story That’s Gaining Ground
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Lowe’s Stock: Hold Now, Buy it When it Dips
- What is the FTSE 100 index?
- ZIM Shipping Stock Soars as the Industry Shows a Bottoming Trend
Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.